LEXINGTON, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced the presentation of a poster describing the Phase 1 trial of CA-170, an oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in the treatment of patients with advanced solid tumors or lymphomas at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place from June 2-6 in Chicago.
In addition, researchers from the Dana-Farber Cancer Institute and Boston Children's Hospital will be presenting information on an investigator-initiated Phase 1 multicenter trial using CUDC-907, Curis' proprietary drug candidate, to treat children and young adults with relapsed or refractory solid tumors, CNS tumors and lymphoma.
Additional information on the presentations can be found below and can be accessed at www.am.asco.org.
CA-170 Poster Presentation:
|Date/Time:||Monday, June 5, 8 AM — 11:30 AM CDT|
|Presentation Title:||Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas|
CUDC-907 Poster Presentation:
|Date/Time:||Sunday, June 4, 8 AM — 11:30 AM CDT|
|Presentation Title:||Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma|
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 email@example.com Media Contact David Schull Russo Partners (212) 845-4271 firstname.lastname@example.org